Kilitch Drugs (India) Limited (IN:KILITCH)
:KILITCH
KILITCH Stock Chart & Stats
₹355.60
₹0.95(0.27%)
At close: 4:00 PM EST
₹355.60
₹0.95(0.27%)
Day’s Range― - ―
52-Week Range₹121.10 - ₹245.00
Previous CloseN/A
Volume65.63K
Average Volume (3M)2.19K
Market Cap
₹4.49B
Enterprise Value₹4.98B
Total Cash (Recent Filing)₹870.13M
Total Debt (Recent Filing)₹836.13M
Price to Earnings (P/E)34.5
Beta0.87
Next Earnings
May 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.27
Shares Outstanding34,961,563
10 Day Avg. Volume2,304
30 Day Avg. Volume2,185
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)2.86
Price to Sales (P/S)2.92
P/FCF Ratio-19.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)7.5
Revenue Forecast (FY)₹2.64B
Bulls Say, Bears Say
Bulls Say
Diversified Revenue Streams (domestic, Exports, Contract Manufacturing)Kilitch’s mix of domestic formulation sales, exports and contract/third‑party manufacturing creates multiple stable revenue channels. Structurally this reduces single‑market dependency, helps smooth capacity utilization and supports recurring revenue and margin resilience over months.
Consistent Revenue And EPS GrowthSustained revenue growth (~13.8%) alongside strong EPS growth (~32%) indicates improving top‑line demand and operational leverage. This combination supports durable profitability, room to reinvest in production or exports, and signals structurally improving unit economics over the medium term.
Stable Balance Sheet With Favorable Equity RatioA strong equity base and only moderate leverage give the company financial flexibility to fund capex, manage working capital, or weather regulatory timing. This structural stability supports investment in capacity and long‑term commercial plans without immediate refinancing pressure.
Bears Say
Weak Cash Flow Conversion And Negative Free Cash Flow GrowthNegative free cash‑flow growth and subpar conversion of earnings into cash reflect structural cash generation issues. Elevated capex has strained liquidity, limiting the firm's ability to self‑fund growth, pay down debt, or return capital without improving operating cash conversion.
Moderate Leverage And Suboptimal Asset UtilizationModerate debt levels combined with ROE that could be higher suggest assets are not fully optimized. This reduces potential upside from financial leverage and indicates room to improve capital efficiency, which could constrain long‑term return enhancement plans.
Exposure To Regulatory, Customer Concentration And Pricing RisksReliance on approvals, export market access and a concentrated customer or product mix creates structural revenue volatility. In generics/formulations, regulatory delays, pricing pressure or loss of key contracts can materially affect volumes and margins over a multi‑month horizon.
Kilitch Drugs (India) Limited News
KILITCH FAQ
What was Kilitch Drugs (India) Limited’s price range in the past 12 months?
Kilitch Drugs (India) Limited lowest stock price was ₹121.10 and its highest was ₹245.00 in the past 12 months.
What is Kilitch Drugs (India) Limited’s market cap?
Kilitch Drugs (India) Limited’s market cap is ₹4.49B.
When is Kilitch Drugs (India) Limited’s upcoming earnings report date?
Kilitch Drugs (India) Limited’s upcoming earnings report date is May 27, 2026 which is in 45 days.
How were Kilitch Drugs (India) Limited’s earnings last quarter?
Kilitch Drugs (India) Limited released its earnings results on Feb 11, 2026. The company reported ₹1.268 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.268.
Is Kilitch Drugs (India) Limited overvalued?
According to Wall Street analysts Kilitch Drugs (India) Limited’s price is currently Overvalued.
Does Kilitch Drugs (India) Limited pay dividends?
Kilitch Drugs (India) Limited pays a Annually dividend of ₹0.5 which represents an annual dividend yield of N/A. See more information on Kilitch Drugs (India) Limited dividends here
What is Kilitch Drugs (India) Limited’s EPS estimate?
Kilitch Drugs (India) Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kilitch Drugs (India) Limited have?
Kilitch Drugs (India) Limited has 34,961,563 shares outstanding.
What happened to Kilitch Drugs (India) Limited’s price movement after its last earnings report?
Kilitch Drugs (India) Limited reported an EPS of ₹1.268 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.637%.
Which hedge fund is a major shareholder of Kilitch Drugs (India) Limited?
Currently, no hedge funds are holding shares in IN:KILITCH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kilitch Drugs (India) Limited
Kilitch Drugs (India) Limited engages in the development and operation of pharmaceutical business in India. The company offers parenteral and nasal products, including gastroenterology, anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, non-steroidal anti-inflammatory, oncology, ophthalmic, and other drugs, as well as vaccines and veterinary products in the form of ampoules, vials, and dry powder injectables. Its parenteral and nasal products also include iron supplements for the treatment of anemia; and metered nasal drops, as well as Klavmox and Onecef products. The company also provides a range of oral formulations, including tablets, capsules, dry syrups, gripe water, and oral powders and liquids in the antibiotic, anti-diabetics, cardiovascular, and other areas. In addition, it offers effervescent tablets and powders, such as ROIPAR, DUREGRA, ROIVIT, and PH-7; and various nutritional products, such as CELTINE. Further, the company provides C-Seal, a topical skin adhesive to hold closely approximated skin edges without marks of sutures and incisions. Additionally, it offers cosmetics and herbal products consisting of a range of oils, lotions, liquids, creams, and paste in skin, personal, and hair care categories, as well as herbal products used in sore throat and prostate problems; and as a supplement for diabetes, obesity, libido, and other conditions. The company also exports its products. Kilitch Drugs (India) Limited was founded in 1978 and is headquartered in Mumbai, India.
Technical Analysis
Ind-Swift Laboratories Ltd.
―
Medicamen Biotech Limited
―
Nectar Lifesciences Ltd.
―
Sakar Healthcare Ltd
―
Venus Remedies Limited
―